君實生物午前漲超3% 特瑞普利單抗獲新加坡衞生科學局批准上市

新浪港股

03-27

君實生物-0.63%

熱點欄目自選股數據中心行情中心資金流向模擬交易

客戶端

　　君實生物（01877）午前上漲3.58%，現報14.46港元，成交額1375.03萬港元。

　　君實生物發佈公告，近日，上海君實生物醫藥科技股份有限公司（以下簡稱“公司”）收到通知，特瑞普利單抗（新加坡商品名：LOQTORZI®）聯合順鉑和吉西他濱用於復發、不能手術或放療的，或轉移性鼻咽癌成人患者的一線治療的上市許可申請獲得新加坡衛生科學局（HSA）批准。特瑞普利單抗成爲新加坡首個且唯一獲批用於鼻咽癌的腫瘤免疫治療藥物。

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：盧昱君

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

no data

沒有相關數據

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2522685390"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522685390\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522685390?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-27 12:00","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2522685390","market":"other","top_or_hot":-1,"title":"君實生物午前漲超3% 特瑞普利單抗獲新加坡衞生科學局批准上市","media":"新浪港股","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/01877.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/688180\">君實生物</a></span><span></span>（01877）午前上漲3.58%，現報14.46港元，成交額1375.03萬港元。</p>\n<p>　　<a href=\"https://laohu8.com/S/01877\">君實生物</a>發佈公告，近日，上海君實生物醫藥科技股份有限公司（以下簡稱“公司”）收到通知，特瑞普利單抗（新加坡商品名：LOQTORZI®）聯合順鉑和吉西他濱用於復發、不能手術或放療的，或轉移性鼻咽癌成人患者的一線治療的上市許可申請獲得新加坡衛生科學局（HSA）批准。特瑞普利單抗成爲新加坡首個且唯一獲批用於鼻咽癌的腫瘤免疫治療藥物。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君實生物午前漲超3% 特瑞普利單抗獲新加坡衞生科學局批准上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君實生物午前漲超3% 特瑞普利單抗獲新加坡衞生科學局批准上市\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪港股</strong><span class=\"h-time small\">2025-03-27 12:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/01877.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<span><a href=\"https://laohu8.com/S/688180\">君實生物</a></span><span></span>（01877）午前上漲3.58%，現報14.46港元，成交額1375.03萬港元。</p>\n<p>　　<a href=\"https://laohu8.com/S/01877\">君實生物</a>發佈公告，近日，上海君實生物醫藥科技股份有限公司（以下簡稱“公司”）收到通知，特瑞普利單抗（新加坡商品名：LOQTORZI®）聯合順鉑和吉西他濱用於復發、不能手術或放療的，或轉移性鼻咽癌成人患者的一線治療的上市許可申請獲得新加坡衛生科學局（HSA）批准。特瑞普利單抗成爲新加坡首個且唯一獲批用於鼻咽癌的腫瘤免疫治療藥物。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-27/doc-ineraiqq4046539.shtml\">新浪港股</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0205439572.USD","symbol_name":"富達亞太股息基金","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-27/doc-ineraiqq4046539.shtml","article_id":"2522685390","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522685390","pubTimestamp":1743048000,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　君實生物（01877）午前上漲3.58%，現報14.46港元，成交額1375.03萬港元。\n　　君實生物發佈公告，近日，上海君實生物醫藥科技股份有限公司（以下簡稱“公司”）收到通知，特瑞普利單抗（新加坡商品名：LOQTORZI®）聯合順鉑和吉西他濱用於復發、不能手術或放療的，或轉移性鼻咽癌成人患者的一線治療的上市許可申請獲得新加坡衞生科學局（HSA）批准。特瑞普利單抗成為新加坡首個且唯一獲批用於鼻咽癌的腫瘤免疫治療藥物。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","LU0205439572.USD":"富达亚太股息基金","BK1583":"高瓴概念","01877":"君实生物","S68.SI":"新加坡交易所","LU0877626530.USD":"FIDELITY ASIA PACIFIC DIVIDEND \"A\" (USD) INC MONTHLY (G)","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU1119993845.HKD":"FIDELITY ASIA PACIFIC DIVIDEND \"A\" (HKDHDG) INC","SG9999000343.SGD":"Schroder Singapore Trust A Dis SGD","LU0192582467.USD":"SCHRODER ISF ASIAN EQUITY YIELD \"A\" (USD) INC MF","SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","LU0188438112.USD":"SCHRODER ISF ASIAN EQUITY YIELD \"A\" ACC","STI.SI":"富时新加坡海峡指数","SG9999001846.SGD":"Schroder Asian Equity Yield A Dis SGD","FSTM.SI":"富时海峡中盘指数","SG9999001135.SGD":"United ASEAN Fund SGD","BK0239":"医药制造","BK1161":"生物科技","SG9999014492.USD":"NIKKO AM ASEAN EQUITY \"A\" (USD) ACC","SG9999014484.SGD":"Nikko AM ASEAN Equity Fund A SGD","LU1920063259.USD":"FIDELITY FUNDS GLOBAL DIVIDEND PLUS \"A\" (USDHDG) INC","LU1920062954.HKD":"FIDELITY FUNDS GLOBAL DIVIDEND PLUS \"A\" (HKDHDG) INC","LU0831103253.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD","LU2401740654.USD":"FIDELITY SUSTAINABLE GLOBAL DIVIDEND PLUS \"A\" (USD) INC","BK6516":"银行与投资服务概念","FSTAS.SI":"富时海峡全股指数","SG9999016042.SGD":"Schroder Singapore Trust A Acc SGD","SGXZ27511609.SGD":"NIKKO AM SINGAPORE DIVIDEND EQUITY \"SGD\" (SGD) ACC","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD","BK6523":"ESG概念","BK6033":"金融交易所和数据","LU2242646235.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) ACC","ES3.SI":"STI ETF","BK1515":"抗疫概念","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0898667661.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD-H","SG9999004360.SGD":"Nikko AM Shenton Thrift Fund SGD"},"translate_title":"Junshi Biotech rose more than 3% before noon, toripalimab was approved for listing by the Singapore Health Sciences Authority","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1,"ES3.SI":0.6,"FSTAS.SI":0.6,"FSTM.SI":0.6,"S68.SI":1,"STI.SI":1},"content_text":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　君實生物（01877）午前上漲3.58%，現報14.46港元，成交額1375.03萬港元。\n　　君實生物發佈公告，近日，上海君實生物醫藥科技股份有限公司（以下簡稱“公司”）收到通知，特瑞普利單抗（新加坡商品名：LOQTORZI®）聯合順鉑和吉西他濱用於復發、不能手術或放療的，或轉移性鼻咽癌成人患者的一線治療的上市許可申請獲得新加坡衞生科學局（HSA）批准。特瑞普利單抗成為新加坡首個且唯一獲批用於鼻咽癌的腫瘤免疫治療藥物。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0}}}

如果下載按鈕點擊無跳轉，請點擊右上角菜單選擇 “在瀏覽器打開”

立即諮詢
下載APP
掃碼下載APP